book chapter · Advances in medical diagnosis, treatment, and care (AMDTC) book series
Parkinson's disease (PD) is recognized as the second most common neurodegenerative disease after Alzheimer's disease. Parkinson's disease is a progressive disease characterized by a progressive loss of dopaminergic neurons of the black substance (SNpc) and dopamine deficiency in the striatal region as well as motor and non-motor symptoms. The main objective of Parkinson's research is to understand the pathogenesis, targets, and development of therapeutic interventions to control disease progression. The use of various agents could be a good strategy for the treatment of PD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4018/978-1-6684-5156-4.ch013
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
